Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity

Table 4 Multiple comparisons of gene expression of Teffs markers in the four studied groups

	Group I naïve	Group II Peg/Riba	Group III ANA+	Group IV control
TNFRSF4OX 40
Group I naïve		bP ≤ 0.01	aP ≤ 0.05	aP ≤ 0.05
Group II Peg/Riba	bP ≤ 0.01		NS (P > 0.05)	bP ≤ 0.01
Group III ANA+	aP ≤ 0.05	NS (P > 0.05)		dP ≤ 0.001
Group IV control	aP ≤ 0.05	bP ≤ 0.01	dP ≤ 0.001
CD4
Group I naïve		bP ≤ 0.01	aP ≤ 0.05	aP ≤ 0.05
Group II Peg/Riba	bP ≤ 0.01		NS (P > 0.05)	aP ≤ 0.05
Group III ANA+	aP ≤ 0.05	NS (P > 0.05)		bP ≤ 0.01
Group IV control	aP ≤ 0.05	aP ≤ 0.05	bP ≤ 0.01
CD25
Group I naïve		bP ≤ 0.01	aP ≤ 0.05	aP ≤ 0.05
Group II Peg/Riba	bP ≤ 0.01		NS (P > 0.05)	bP ≤ 0.01
Group III ANA+	aP ≤ 0.05	NS (P > 0.05)		dP ≤ 0.001
Group IV control	aP ≤ 0.05	bP ≤ 0.01	dP ≤ 0.001
Interferon-γ
Group I naïve		bP ≤ 0.001	bP ≤ 0.001	aP ≤ 0.05
Group II Peg/Riba	bP ≤ 0.001		NS (P > 0.05)	aP ≤ 0.05
Group III ANA+	bP ≤ 0.001	NS (P > 0.05)		bP ≤ 0.01
Group IV control	aP ≤ 0.05	aP ≤ 0.05	bP ≤ 0.01

ANA: Antinuclear antibody; NS: Non significant.